Expanded Portfolio for Biomolecules Purification Announced
Oct 12 2017 Read 473 Times
With the increased interest in the purification of a wider variety of biomolecules, the portfolio of Kromasil 300 Å has been expanded to support these applications.
The Kromasil 300 Å line of HPLC products is now shipping with C18, C8, C4 and diC4 derivatisations for scientists and engineers exploiting selectivity and loadability for purification of API and impurity isolation. In particular, the new Kromasil 300 Å diC4 has different characteristic than a classic C4, enabling new opportunities to remove impurities from peptide and protein crudes.
For more information, visit www.kromasil.com
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles Chromatography - Visiting the 15th International Symposium - New Application Book Offers Expertise in GPC Analysis - Same Separation, Speedier Solution Mass S...
View all digital editions
Mar 22 2018 Istanbul, Turkey
Mar 23 2018 Beijing, China
Mar 27 2018 Guangzhou, China
Mar 28 2018 Lyon, France
Apr 02 2018 Suntec City, Singapore